| Literature DB >> 34195468 |
Kanimolli Arasu1, Chung Yuan Chang1, Soon Yee Wong1, Shu Hwa Ong1, Wai Yew Yang1, Megan Hueh Zan Chong1, Meenal Mavinkurve2, Erwin Jiayuan Khoo2, Karuthan Chinna3, Connie M Weaver4, Winnie Siew Swee Chee1.
Abstract
BACKGROUND: Recruitment and retention in longitudinal nutrition intervention studies among children is challenging and scarcely reported. This paper describes the strategies and lessons learned from a 1-year randomized double-blind placebo-controlled trial among pre-adolescent children on the effects of soluble corn fiber (SCF) on bone indices (PREBONE-Kids).Entities:
Keywords: 25-OHD, serum 25-hydroxyvitamin D; BAP, bone-specific alkaline phosphatase; BMC, bone mineral content; BMD, bone mineral density; CTX, carboxy-terminal collagen crosslinks; Calcium; Compliance; DXA, dual-energy X-ray absorptiometry; MET, total metabolic equivalent; OC, osteocalcin; P1NP, procollagen type 1 amino-terminal propeptide; PBM, peak bone mass; Pre-adolescent children; SCF, soluble corn fibre; Soluble corn fiber; Study retention; iPTH, intact parathyroid hormone
Year: 2021 PMID: 34195468 PMCID: PMC8233130 DOI: 10.1016/j.conctc.2021.100801
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
Schedule of enrollment, interventions and measurements for study.
| Activities | Enrollment | Timeline | ||
|---|---|---|---|---|
| Baseline | 6 months | 12 months | ||
| Informed consent | X | |||
| Eligibility screening | X | |||
| Study Run In | X | |||
| Randomization | X | |||
| X | X | X | ||
| X | X | X | X | |
| X | ||||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | ||||
| X | ||||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
| X | X | X | ||
Abbreviations: BMD: bone mineral density, BMC: bone mineral content; CTX; c-terminal telopeptide, BAP; bone alkaline phosphate, P1NP; procollagen type 1 N propeptide, OC; osteocalcin, iPTH; intact parathyroid hormone; 25-OHD:serum 25 hydroxyvitamin D.
Study retention rates at baseline, 6 months and 12 months.
| Time point | Retention (n,%) | ||
|---|---|---|---|
| Baseline (N = 243) | 6 months (N = 204) | 12 months (N = 201) | |
| 600 mg Ca | 60 (100.0%) | 53 (88.3%) | 52 (86.7%) |
| 12 g SCF | 61 (100.0%) | 52 (85.2%) | 51 (83.6%) |
| 600 mg Ca+12 g SCF | 61 (100.0%) | 47 (77.0%) | 47 (77.0%) |
| Placebo | 61 (100.0%) | 52 (85.2%) | 51 (83.6%) |
Compliance rates at initial, 6 and 12 months.
| Trial period | Total | Ca (N = 52) | SCF (N = 51) | SCF + Ca (N = 47) | Placebo (N = 51) | p value |
|---|---|---|---|---|---|---|
| Initial 1st month | 85.0 ± 30.0 | 83.8 ± 22.2 | 88.3 ± 25.2 | 84.7 ± 37.0 | 83.3 ± 33.5 | 0.794 |
| 6 months | 82.9 ± 24.0 | 79.2 ± 23.6 | 85.7 ± 25.6 | 86.0 ± 20.6 | 81.0 ± 25.7 | 0.384 |
| 12 months | 78.7 ± 23.8 | 74.4 ± 25.9 | 83.6 ± 22.8 | 80.3 ± 21.0 | 76.5 ± 24.6 | 0.209 |
| Frequency of participants in categories of compliance (n,%) | ||||||
| Good ≥80% | 109 (54.2) | 23 (43.4) | 28 (56.0) | 33 (64.7) | 25 (53.2) | |
| Moderate 50–79% | 58 (28.9) | 18 (34.0) | 11 (22.0) | 13 (25.5) | 16 (34.0) | |
| Poor <50% | 34 (16.9) | 12 (22.6) | 11 (22.0) | 5 (9.8) | 6 (12.8) | |
Mean compliance rate of participants expressed as mean ± SD.
Comparison among groups tested with two-way ANOVA (p > 0.05).
Baseline characteristics of participants (N = 243).
| Characteristics | Study participants (N = 243) |
|---|---|
| Age | 10.1 ± 1.0 |
| Gender (n,%) | |
| Boys | 127 (52.3) |
| Girls | 116 (47.7) |
| Ethnicity (n,%) | |
| Malay | 220 (90.5) |
| Indian | 23 (9.5) |
| Pubertal stage (n, %) | |
| Tanner 1 | 230 (94.7) |
| Tanner 2 | 13 (5.3) |
| Weight (kg) | 34.0 ± 12.1 |
| Height (cm) | 135.8 ± 9.1 |
| BMI (kg/m2) | 18.0 ± 4.5 |
| BMI category (n, %) | |
| Thinness | 21 (8.6) |
| Normal | 142 (58.4) |
| Overweight | 39 (16.1) |
| Obese | 42 (17.3) |
| Lean mass (kg) | 10.9 ± 7.1 |
| Fat mass (kg) | 21.8 ± 5.3 |
| Pubertal stage (n, %) | |
| Tanner 1 | 230 (94.7) |
| Tanner 2 | 13 (5.3) |
| Energy intake (kcal/day) | 1457 ± 450 |
| Calcium intake (mg) | 349 ± 180 |
| Physical activity (MET) | 822.5 ± 447.2 |
| TB BMD (g/cm2) | 0.768 ± 0.075 |
| TB BMC (g) | 1129.45 ± 231.59 |
| TB BMD Z-score | 0.8 ± 1.0 |
| LS BMD (g/cm2) | 0.725 ± 0.091 |
| CTX (ng/ml) | 0.96 ± 0.4 |
| BAP (ug/l) | 72.8 ± 25.3 |
| P1NP (ng/mL) | 617.1 ± 237.0 |
| OC (ng/mL) | 49.8 ± 21.7 |
| Serum 25-OHD (ng/mL) | 43.9 ± 14.5 |
| Deficiency (<30 nmo/L) | 46 (18.9) |
| Insufficient (30–40 nmol/L) | 57 (23.5) |
| Sufficient (>40 nmol/L) | 140 (57.6) |
| iPTH (pmol/L) | 3.33 ± 2.14 |
Abbreviation: TB: total body; LS: lumbar spine; BMD: bone mineral density, BMC: bone mineral content; CTX: c-terminal telopeptide; BAP: bone alkaline phosphate, P1NP: procollagen type 1 N propeptide: P1NP; OC: osteocalcin, iPTH: parathyroid.
Data expressed as n (%) for ethnicity, BMI and pubertal staging while all other data is presented as mean ± SD.
Classification for serum 25-OHD is based on IOM 2011 [27].
Feedback on the study conduct by voluntary response from participants (N = 85).
| Domains | Satisfied n (%) | Not satisfied n (%) |
|---|---|---|
| Overall study conduct | 81 (95.3%) | 4 (4.7%) |
| Activities conducted | 81 (95.3%) | 4 (4.7%) |
| Taste of the supplement | 77 (90.6%) | 8 (9.4%) |
| Incentives provided | 84 (98.8%) | 1 (1.2%) |
| Rapport with research team | 81 (95.3%) | 4 (4.7%) |